18F-fluorodeoxyglucose-positron emission tomography/computed tomography after one cycle of chemotherapy in patients with diffuse large B-cell lymphoma: results of a Nordic/US intergroup study. Issue 7 (July 2015)

• Record Type: Journal Article
• Authors: Mylam, Karen Juul; Kostakoglu, Lale; Hutchings, Martin; Coleman, Morton; Lamonica, Dominick; Czuczman, Myron S.; Diehl, Louis F.; Nielsen, Anne L.; Jensen, Paw; Loft, Annika; Hendel, Helle W.; Iyer, Victor; Leppä, Sirpa; Jyrkkiö, Sirkku; Holte, Harald; Eriksson, Mikael; Gillstrøm, Dorte; Hansen, Per B.; Seppänen, Marko; Hjorthaug, Karin; Brown, Peter de Nully; Pedersen, Lars M.
• Is Part Of: Leukemia & lymphoma. Volume 56:Issue 7(2015:Jul.)
• Page Start: 2005
• Page End: 2012
• Publication Date: 2015-07
• Subjects: Leukemia -- Periodicals; Lymphomas -- Periodicals; 616.99419
• DOI: 10.3109/10428194.2014.975800
• Languages: English
• ISSNs: 1042-8194

Abstract

<abstract> <title>Abstract</title> <p>We evaluated the predictive value of interim positon emission tomography (I-PET) after one course of chemoimmunotherapy in patients with newly diagnosed diffuse large B-cell lymphoma (DLBCL). One hundred and twelve patients with DLBCL were enrolled. All patients had PET/computed tomography (CT) scans performed after one course of chemotherapy (PET-1). I-PET scans were categorized according to International Harmonization Project criteria (IHP), Deauville 5-point scale (D 5PS) with scores 1–3 considered negative (D 5PS &gt; 3) and D 5PS with scores 1–4 considered negative (D 5PS = 5). Ratios of tumor maximum standardized uptake value (SUVmax) to liver SUVmax were also analyzed. We found no difference in progression-free survival (PFS) between PET-negative and PET-positive patients according to IHP and D 5PS &gt; 3. The 2-year PFS using D 5PS = 5 was 50.9% in the PET-positive group and 84.8% in the PET-negative group (<italic>p</italic> = 0.002). A tumor/liver SUVmax cut-off of 3.1 to distinguish D 5PS scores of 4 and 5 provided the best prognostic value. PET after one course of chemotherapy was not able to safely discriminate PET-positive and PET-negative patients in different prognostic groups.</p> </abstract>